↓ Skip to main content

Dove Medical Press

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
3 news outlets
twitter
5 X users
facebook
2 Facebook pages

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
75 Mendeley
Title
Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial
Published in
Neuropsychiatric Disease and Treatment, March 2015
DOI 10.2147/ndt.s78696
Pubmed ID
Authors

Vahid Farnia, Mehdi Shirzadifar, Jalal Shakeri, Mansour Rezaei, Hafez Bajoghli, Edith Holsboer-Trachsler, Serge Brand

Abstract

A substantial disadvantage of psychopharmacological treatment of major depressive disorder (MDD) with selective serotonin-reuptake inhibitors (SSRIs) is the impact on sexual dysfunction. The aim of the present study was to investigate whether the oil of Rosa damascena can have a positive influence on SSRI-induced sexual dysfunction (SSRI-I SD) of male patients who are suffering from MDD and are being treated with SSRIs. In a double-blind, randomized, and placebo-controlled clinical trial, a total of 60 male patients treated with an SSRI and suffering from MDD (mean age =32 years) and SSRI-I SD were randomly assigned to take either verum (R. damascena oil) or a placebo. Patients completed self-ratings of depression and sexual function at baseline, at 4 weeks later, and at the end of the study, 8 weeks after it started. Over time, sexual dysfunction improved more in the verum group than in the control group. Improvements were observed in the verum group from week 4 to week 8. Self-rated symptoms of depression reduced over time in both groups, but did so more so in the verum group than in the control group. This double-blind, randomized, and placebo-controlled clinical trial showed that the administration of R. damascena oil ameliorates sexual dysfunction in male patients suffering from both MDD and SSRI-I SD. Further, the symptoms of depression reduced as sexual dysfunction improved.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 74 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 16%
Student > Ph. D. Student 9 12%
Student > Bachelor 9 12%
Researcher 8 11%
Student > Doctoral Student 4 5%
Other 12 16%
Unknown 21 28%
Readers by discipline Count As %
Medicine and Dentistry 15 20%
Psychology 10 13%
Agricultural and Biological Sciences 9 12%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 4 5%
Other 10 13%
Unknown 22 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2024.
All research outputs
#1,395,174
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#181
of 3,132 outputs
Outputs of similar age
#17,290
of 270,996 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#10
of 69 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,996 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.